Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, 48-Week Study to Assess the Safety, Tolerability and Activity of Raltegravir When Replacing the Ritonavir-boosted PI Component of HAART in HIV-Infected Individuals With Viral Load Suppression on a Ritonavir-Boosted PI Containing Regimen.

NCT00528892 is registered in ClinicalTrials.gov with Hospital Clinic of Barcelona as lead sponsor.

NCT NCT00528892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00528892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, 48-Week Study to Assess the Safety, Tolerability and Activity of Raltegravir When Replacing the Ritonavir-boosted PI Component of HAART in HIV-Infected Individuals With Viral Load Suppression on a Ritonavir-Boosted PI Containing Regimen.
Lead sponsor
Hospital Clinic of Barcelona
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2008
Completion date
March 31, 2010
Enrollment
282 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections